General Updates | The genetic landscape of MDS: how this is improving & impacting the development of therapies
Jan Bewersdorf
• 6 Oct 2023
Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, shares insights into advances made in the understanding of the genetic landscape of myelodysplastic syndromes (MDS). Dr Bewersdorf explains that while there have been advances in this space, more research needs to be conducted to improve the development of targeted therapies. Targeting splicing mutations and TP53 mutations may be of interest, with ongoing trials exploring these approaches. This interview was recorded virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
